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Abstract
Background: The aim of this study was to analyze and describe cases of ovarian cancer in
pregnant women treated at our center and to review the literature concerned, and to discuss the
rationale for therapy.
Methods: Twenty-Three patients of ovarian malignancies during pregnancy were treated at Vali-
Asr Hospital between 1991 and 2002. Data on treatment and follow-up were evaluated.
Results: The incidence of ovarian carcinoma associated with pregnancy in our series was 0.083/
1000 deliveries. Eleven (47.8%) were found with ovarian malignant germ cell tumors, five (21.7%)
with low malignant potential tumors, four (17.4%) with invasive epithelial tumors, and three (13%)
with sex cord stromal tumors. Seventeen (73.9%) of the patients were diagnosed in stage I and had
complete remission. Five of the six in advanced stage died. The mean follow-up was 36.3 months.
The prognosis was significantly related with stage and histological type (P < 0.05). Sixteen healthy
live babies were recorded in this group, and two premature newborn died of respiratory distress
syndrome. Chemotherapy was administered to 44% of the patients, in two cases during pregnancy.
Overall survival at 5 years was 61%. In most of case conservative surgical treatment could be
performed with adequate staging and debulking.
Conclusion:  Early finding of ascitis by ultrasound and persistent large ovarian mass during
pregnancy may be related to malignancy and advanced stage. Pregnant women in advanced stage of
ovarian cancer seem to have poor prognosis.
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Background
Ovarian cancer is the second most frequent gynecological
cancer complicating pregnancy except for cervical carci-
noma. Although the overall incidence of ovarian cancer is
very low (one in 12500–25000 pregnancies), the routine
use of ultrasound in pregnancy has led to more frequent
findings of adnexal masses, making diagnosis and man-
agement increasingly challenging. The estimated inci-
dence of ovarian tumors is approximately one in 1000
pregnancies. Of those tumors approximately 3–6% is
malignant [1-4]. These tumors are relatively asympto-
matic and could be seen in a routine ultrasonographic
scan [5]. In the absence of large prospective randomized
trials and cohort studies, it is difficult to know how best to
manage these patients. In dealing with a pregnant woman
with ovarian cancer, one must consider the effects of the
malignancy on the woman and the fetus and how the
pregnancy itself can change the diagnostic procedures and
therapy.
Surgical treatment is the same as that in nonpregnant
patients. Further surgical treatment depends on the stage,
type, and presence of the metastatic pathway [6-8]. This
study is a retrospective review of our experience of malig-
nant ovarian tumors diagnosed in pregnancy and treated
in our center between 1991 and 2002.
Methods
This is a clinical history retrospective review of patients
with ovarian cancer during pregnancy who were diag-
nosed and treated at Vali-e- Asr Gynecologic oncology
department during a 11-year period between 1991 and
2002. 607 cases of ovarian cancer were treated in this
center during 11 year-period. Twenty-three of them were
detected during gestation, at delivery, or in the puerper-
ium. Due to our Clinic is a referral center, Eighteen of
them were from our obstetrics department, while 227500
deliveries were done in our obstetric clinic during the
same period. The others were transferred from other hos-
pitals. Of these patients that were referred, only patients
were selected for come to study that surgical staging for
these to be done. Specialized pathologists in our institu-
tion reviewed pathology specimens and biopsies for all 23
patients. The 1988 FIGO Staging System was retrospec-
tively assigned for each case after reviewing their operative
reports and microscopy slides. All patients with the diag-
nosis of ovarian immature teratomas were histologically
graded according to the criteria of Norris. No patient had
positive past medical history or any relative family his-
tory. Patients were followed up with clinical, tumor
marker, and radiologic assessments. Follow-up informa-
tion was recorded up to the date of last contact or death.
Responses to the treatment were evaulated using World
Health Organization criteria. Complete response or cure
was defined as complete resolution of all clinically and
radiologically measurable diseases.
Results
The age of the patients ranges from 20 to 40 years (with a
median range of: 29.2 years). In this group, histopatho-
logic characteristics included malignant germ cell tumors
(n = 11), malignant epithelial ovarian tumors (n = 4), low
malignant potential (LMP) tumors (n = 5), and sex cord-
stromal tumors (SCT) (n = 3). Seventeen patients (73.9%)
were in stage I, 5 two (8.7%) in stage II, three (13 %) in
stage III, and one (4.3%) in stage IV. The clinical and path-
ologic profiles of 23 patients were shown in Table 1.
The most common of patient's initial symptom was pelvic
or adnexal mass (11/23, 47.8%). These masses were
Table 1: Characteristics of patients with ovarian tumors during pregnancy
Histological type EOC LMPT(BOT) MOGCT SCST
No. of patients 4 (17.4%) 5 (21.7%) 11 (47.8%) 3(13%)
Stage I 1 5 8 3
Stage>I Stage III(2)
Stage IV(1)
- Stage II(1)
Stage III(1)
-
Adjuvant chemotherapy 3/4 - 6/11 1/3
Chemotherapy during Pregnancy 1/3 - 1/6 -
Recurrence 3
DOD = 3
Stage III(2)
Stage IV(1)
-1
DOD = 1
Stage III [(IMT(grade 3)]
1(JGCT)
EOC: epithelial ovarian cancer; LMPT: Low malignant potential tumor; BOT: Borderline ovarian tumor; MOGCT: malignant ovarian germ cell 
tumors; SCST: sex cord-stromal tumors. DOD: Death of disease ; IMT: Immature teratoma; JGCT: Juvenile granulose cell tumorBMC Pregnancy and Childbirth 2008, 8:3 http://www.biomedcentral.com/1471-2393/8/3
Page 3 of 7
(page number not for citation purposes)
detected accidentally by routine pelvic or ultrasound
examinations. Mean of ovarian size in these were 8.5 cm.
Three patients (13.6%) presented with abdominal pain,
and seven (30.4%) with swelling and ascites. Two (8.7%)
patients were asymptomatic and found tumors in opera-
tion accidentally, of which one malignant papillary serous
tumor and another dysgerminoma was diagnosed in
laparotomy for cesarean section. Five of the seven patients
with ascites were in advanced stage (stages III-IV) and died
finally. Another two patients with negative cytology of
ascites had dysgerminoma and immature teratoma and
were free of disease at the last follow-up.
Twenty-two patients were diagnosed during pregnancy,
and one in the puerperium. Table 2 presents the alloca-
tion and outcomes of patients according to duration of
pregnancy at diagnosis. Six were found in the first trimes-
ter, and two of them had abortion. One of these who was
diagnosed with disseminated ovarian endometrioid can-
cer at 6 weeks died within 12 months, though she had
accepted aggressive cytoreductive surgery and adjuvant
chemotherapy. In two women, tumors were found by pre-
natal examinations at 13 weeks of gestation, and both
undertook observations until their terms. The former was
with stage Ia serous borderline tumor and got free of dis-
ease without additional treatment. The latter that were
diagnosed with stage Ia dysgerminoma in operation.
Another woman with serous borderline tumor was found
at 14 weeks of gestation. She had operation preserving
pregnancy at 14 weeks of gestation and got a satisfactory
outcome for mother and fetus. Ten gravidas were detected
in the second trimester, and all accepted instant opera-
tions preserving pregnancy respectively. Exclude five
patients that had preterm labor, no perioperative compli-
cation was observed in these patients having conservative
surgeries during the second trimester.
Four patients underwent Cesarean sections and immedi-
ate surgery for tumor directly after detection in the third
trimester, of which three with early-stage malignancies
had satisfactory outcomes and one in stage III c died.
Another one gravidas accepted 11-week observation
awaiting fetal maturity before their aggressive surgeries.
She had Disgerminoma stage Ia and got complete remis-
sion. One with endodermal sinus tumor (EST) stage I
received chemotherapy and got complete remission. One
patient in the puerperium had immediate surgery for
tumor with stage II disgerminoma that received chemo-
therapy and had complete remission.
All patients undertook surgery as the initial treatment.
Surgery varied from biopsy to total abdominal hysterec-
tomy and unilateral or bilateral salpingo-oophorectomy,
omentectomy, and debulking. In young women inter-
ested in further fertility and with LMP tumors and early-
stage germ cell tumors, surgery was conservative. Two
cases of advanced cancer were treated by primary cytore-
ductive surgery. Two cases underwent secondary debulk-
ing. In 10 cases (43.7%), additional chemotherapies were
administered. Two patients received chemotherapy with
the fetus in utero. One patients with papillary serous ade-
nocarcinoma stage IIIc that received 4 course of taxol plus
carboplatin (T+C) from 20 weeks of gestation. she under-
went Cesarean section and optimal debulking in 37 weeks
of gestation. After termination of pregnancy she received
3 course of T+C and 3 course of interaperitoneal carbopl-
atin for consolidation therapy.4 months after she was
recurred and received second line chemotherapy. She died
38 months after. Another patient with immature teratoma
grade 3, stage III that received 2 course of bleomycin,
etoposide and cisplatin (BEP) from 29 weeks of gestation.
These patients had good pregnancy outcome but all of
these died.
The mean follow-up was 36 months (range, 12–73
months). In this period the patients followed with meas-
urement of CA125 level, ultrasonography and Computed
tomography if to be indication. The overall expected 5-
year survival was 61%. Invasive epithelial cancer had the
poorest outcome in all histologic types. All patients in
early stage except the one lost were free of disease, whereas
80% of the five in advanced stage died within 2 years and
all of them died within half year. Of the four patients in
advanced disease, three were with invasive epithelial can-
cers, and one with immature teratoma. All three patients
with epithelial cancers died.
Table 2: Ovarian malignancy identification according to duration of pregnancy and their outcomes
Stage of pregnancy Number of patients Outcomes of patients Outcomes of pregnancy
DFS Dead Vaginal deliveries CS
Trimester 1 6 5 1 4 0
Trimester 2 10 7 3 5 1
Trimester 3 6 5 1 2 3
Puerperium 1 1 0 1 0
DFS: Disease free survival; CS: Cesarean sectionBMC Pregnancy and Childbirth 2008, 8:3 http://www.biomedcentral.com/1471-2393/8/3
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No congenital malformations were detected in all 16 new-
borns. Sixteen healthy term infants were delivered by
twenties normal vaginal births and four Cesarean sec-
tions. Other five premature newborns were born by nor-
mal vaginal births, of which two died of respiratory
distress syndrome due to delivered before 26 weeks. Nei-
ther dystocia nor tumor metastasis to placenta and fetus
was recorded.
Discussion
Fewer than 20% of epithelial ovarian cancers occur in pre-
menopausal women. However, now that ultrasound
monitoring is routinely used during pregnancy, adnexal
mass findings in pregnant women are relatively common.
Ovarian cancer is the second most frequent gynecologic
cancer complicating pregnancy [1-3].
Incidence of ovarian malignancies detected during preg-
nancy was 1/15000 to 1/32000 pregnancies in most
reports [3-9]. Ueda and Ueki reported a higher incidence
with 1/1684 pregnancies [6], but population-selective
bias was not excluded in their study. In our series, carci-
noma of the ovary during pregnancy remains a rare event
and occurs in 0.083/1000 deliveries. Similar incidence as
0.08/1000 deliveries has been recently published in Saye-
dur's study and PUMCH[1,4]. In the most numerous and
most recently informed series by Leiserowitz [10], with
202 cases of ovarian cancer in pregnant women, there is a
0.19% proportion of ovarian mass diagnosed during preg-
nancy, of which 2.15% were cases of ovarian cancer.
Our method and results were similar to Zhao et al. [3].
Most of our patients were clinically asymptomatic at the
time of presentation. Such phenomenon has been
described previously [7,8]. Ovarian tumors are estimated
to occur in 1 in 81 pregnancies to 1 in 2489 pregnancies,
and of these 2–5% are malignant [3,4,8-12]. With the
widespread use of routine prenatal ultrasound, the find-
ing of an adnexal mass in pregnancy is an increasingly
common occurrence [4,13]. Furthermore, our data reveals
that the early finding of ascites by ultrasound may be
closely related with malignancy and advanced stage and
bad prognosis. This implication previously investigated
by Zanotti, et al. [4].
The majority of ovarian cancers associated with pregnancy
are diagnosed at an early stage, when disease is still con-
fined to the ovary [4,14]. It seems that the distribution of
different histologic types of ovarian cancers during preg-
nancy is similar to that of nonpregnant women in the cor-
responding reproductive-age group (Table 3)[4,14-16]. In
our series, germ cell tumors and epithelial tumors of LMP
were much more prevalent than other types of malignan-
cies in pregnancy. The most common subtype of germ cell
tumor in our study was disgerminoma, and next were
immature teratoma and EST, which are similar to another
reportes [11-18]. Reflecting trends in the reproductive-age
population, the majority of ovarian epithelial tumors
diagnosed during pregnancy are tumors of LMP and most
are confined to the ovary [12,14]. Granulose cell tumor is
the most common subtype of ovarian cancers derived
from the specialized gonadal stroma, presenting as the
juvenile form in young females[19]. Similar events have
been seen in our group and Zanotti [4]. In the largest
reported series of SCTs diagnosed during pregnancy, two
of their patients were associated with virilization, and one
with vaginal bleeding [19]. Masculine signs in pregnancy
were present in two of five patients with SCT in Duska's
report [20] but were absent in Gurbuz's case [21]. Young
et al. [19] have revealed the biologic behavior of SCTs
diagnosed during gestations was similar to that of tumors
unassociated with pregnancy. Thus, complicating gesta-
tions could not make worse the prognosis of ovarian
malignancies if adequate treatments were applied in time,
but in our series one patient with juvenile granulose cell
tumor was multiple recurred and died 48 months after.
Table 3: Allocation of ovarian in pregnancy by histology of tumor in literature
Author/year
Histopathology Dgani/1989(12) Copeland/1996(13) Zanotti/2000(2) PUMCH/2003 This study
Epithelial malignancies 65%(15/12) 37.5% 33–40% 50%(11/22) 39.1%
LMP 35%(8/23) - 2/3 27.3%(6/22) 21.7%
Invasive epithelial 30%(7/23) - 1/3 22.7%(5/22) 17.4%
Germ cell malignancies 17%(4/23) 45% 30–33% 40.9%(9/22) 47.8%
SCTs 13%(3/23) 10% 17–20% 9.1%(2/22) 13%
Others 5%(1/23) 7.5% 12–13% 0.(0/22) 0
LMP : Low malignant potential ; SCT: sex cord-stromal tumorsBMC Pregnancy and Childbirth 2008, 8:3 http://www.biomedcentral.com/1471-2393/8/3
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There were reports about the rapid growth and recurrence
of ovarian germ cell tumors during pregnancy[4,22,36].
Most of these reported cases got satisfactory results after
standard postoperative chemotherapy. Mooney et al. [23]
Described multiple areas of microinvasion in eight of ten
reported serous tumors of LMP diagnosed during preg-
nancy. However, these aggressive features seemed to
regress with termination of the pregnancy, and all ten
cases got free of disease. No such invasive behaviors were
found in our series. Obstetric complications were numer-
ous in the studies of Karlen et al. [22] and Bakri et al. [11],
who noted that 47–50% of patients had associated com-
plications such as Cesarean section and observed that the
management of pregnancy was frequently altered to
accommodate for the presence of the ovarian tumor.
Adverse effect on the fetus was demonstrated by the 0–
24% fetal death rate presumably attributable to alteration
in the obstetric management [11,22]. Our data show
two(8.6%) premature fetuses died of respiratory distress
syndrome. Zemlickis et al. [24] documented that maternal
cancer probably caused suboptimal intrauterine condi-
tions and increased risk of stillbirth (a 4.23 relative risk)
in women who did not receive chemotherapy. The higher
overall survival rates in our series were attributed to
78.3% of patients in stage I of the disease and more
patients with germ cell tumors and tumors of LMP. But
Overall 5-years survival was 61%. Advanced stage of dis-
ease and special histologic type, especially invasive epithe-
lial cancer, were the important poor prognostic factors
[24-28]. Unilateral, simple-appearing masses less than 5
cm in diameter detected in the first trimester often repre-
sent cysts that are functional in nature. For an adnexal
mass exceeding 6 cm, with complex structure or ascites or
persisting 16 gestational weeks, surgical intervention is
important to obtain a final histologic diagnosis and rule
out malignancy [26]). Elective surgery for tumors with
low suspicion of malignancy should be delayed until the
second trimester (17–19 weeks of gestation), a time asso-
ciated with a reduced risk of spontaneous abortion, hor-
monal independence of the corpus luteum of pregnancy,
and resolution of functional cysts in the vast majority of
cases[27,28]. Our experience shows adnexal surgery in the
second trimester is safe for mother and fetus. We had
8.7% abortion and 70% of patients had full term preg-
nancy.
The spontaneous abortion rate after surgery in the first tri-
mester was documented as 10%, 76.3% patients progress-
ing to full-term delivery [29]. Hysterectomy during
pregnancy is rarely indicated, unless it contributes signifi-
cantly to tumor debulking [4,13]. As follows, we summa-
rized our therapeutic experience and others according to
histologic types.
LMP tumors differ from invasive epithelial ovarian cancer
in their indolent behavior and good prognosis. In our
study, all five LMP tumor patients had no evidence of dis-
ease at the end of follow-up whether they received aggres-
sive surgery and postoperative chemotherapy or not. All
six cases in Gotlieb's report[30] with immediate conserv-
ative surgery preserving pregnancy had satisfactory out-
comes. Since there was no established benefit from
postoperative therapy for tumors of LMP even in late-
stage diseases[31] and most recurrences were still border-
line [30-35], adjuvant chemotherapy should not be dic-
tated especially for cases in pregnancy. Invasive epithelial
cancer has the worst prognosis in all types of ovarian can-
cers. In our Experience, none of the three with advanced
disease survived. Contrarily, one well differentiated stage
I patients were still alive. All had postoperative platinum-
based 12 chemotherapy and in one patients combination
chemotherapy had done during pregnancy. For these can-
cers, timely cytoreduction surgeries should be applied,
and postoperative adjuvant chemotherapy is indicated,
except for well-differentiated stage IA tumors[6]. It should
be stressed that chemotherapy is contraindicated during
the first trimester of pregnancy because of the high rate of
abortion[22,36] and abnormal fetal development[39],
whereas it is compatible in the second or third trimester
when the risk of congenital malformation for fetuses
exposed to chemotherapy is no greater than the general
population[24,37]. However, there are non teratogenic
effects of chemotherapy such as intrauterine growth
restriction (low birth weight) or effects on the central
nervous system as it develops throughout preg-
nancy[24,38-40]. Until now, no studies have evaluated
the long-term consequences for children exposed to intra-
uterine chemotherapy. Breastfeeding during cytotoxic
chemotherapy has been discouraged in general [39-42].
There is no convincing evidence that a synergistic increase
in malformations occurs with the use of multiagent regi-
mens as opposed to treatment with a single cytotoxic
agent [38]. The literature contains numerous reports of
bleomycin, cisplatin, and etoposide used in pregnancy
with no untoward effects [3,41-44]. Several reported cases
in the literature has described the use of adjuvant cisplatin
and cyclophosphamide initiated in the second trimester
of pregnancy, all with good response to therapy and sub-
sequent delivery of a healthy fetus [43-46]. There were few
case reports describing the combined use of paclitaxel and
carboplatin in human pregnancy, and there seems to be
no significant fetal toxicity when administered during the
second or third trimester [46-49].
Conclusion
Early finding of ascitis by ultrasound and persistent large
ovarian mass during pregnancy may be related to malig-
nancy and advanced stage. Pregnant women in advanced
stage of ovarian cancer seem to have poor prognosis.BMC Pregnancy and Childbirth 2008, 8:3 http://www.biomedcentral.com/1471-2393/8/3
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Chemotherapy is not contraindicated during the second
or third trimester, but the choice of couple must be con-
sidered.
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